Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly.

@article{Kirito2018RuxolitinibIE,
  title={Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly.},
  author={Keita Kirito and Kenshi Suzuki and Koichi Miyamura and Masahiro Takeuchi and Hiroshi Handa and Shinichiro Okamoto and Brian Gadbaw and Kyosuke Yamauchi and Taro Amagasaki and Kazuo Ito and Masayuki Hino},
  journal={International journal of hematology},
  year={2018},
  volume={107 2},
  pages={
          173-184
        }
}
Ruxolitinib, a potent JAK1/JAK2 inhibitor, was found to be superior to the best available therapy (BAT) in controlling hematocrit, reducing splenomegaly, and improving symptoms in the phase 3 RESPONSE study of patients with polycythemia vera with splenomegaly who experienced an inadequate response to or adverse effects from hydroxyurea. We report findings… CONTINUE READING